Proposing Vascepa (Icosapent Ethyl) as Supplemental Treatment Targeting the Underlying Causes of Persistent, Post-Viral Symptoms Associated with COVID-19: A Case Series
Abstract
Current treatment options of post-viral COVID-19 symptoms lack conclusive evidence of success in infected individuals, leaving a desperate need for alternative treatments. In this study, we propose the use of icosapent ethyl (IPE), a pure esterized form of omega-3 fatty acid eicosapentaenoic acid (EPA), for its current use as a cell membrane stabilizer, anti-inflammatory and antithrombotic agent. This case series consists of patients, all of which experienced persistent post-viral symptoms of COVID-19 weeks to months after incidence of infection. Each patient reported considerable improvement of various COVID-19 symptoms including post-exertional malaise, cognitive impairment, and dermatologic complaints, primarily hair loss and onycholysis. As a result, we believe each of these individual outcomes collectively provide a starting point in demonstrating the potential success of IPE in treating persistent COVID-19 symptoms brought on by systemic hyperinflammation and hypercoagulation. In doing so, we hope to spark additional research detailing clinical outcomes of IPE administration to treat COVID-19.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.